甲氨蝶呤与吗替麦考酚酯单药治疗非感染性眼部炎症性疾病控制效果的比较
该研究基于全身免疫抑制治疗眼病队列研究的回顾性分析,纳入352例在4家三级葡萄膜炎门诊接受甲氨蝶呤(MTX)或吗替麦考酚酯(MMF)单药免疫抑制治疗的患者,采用边际结构模型加权模拟临床试验。结果显示MMF达到激素节约成功的速度较MTX更快(风险比=0.68,95%CI:0.46-0.99),2至8个月各时间点MMF成功比例更高,9个月时趋同;两组因毒性停药发生率相似。作者认为MMF平均可能比MTX更快实现激素节约成功。
要点
- MMF达到激素节约成功的时间较MTX更短(风险比=0.68,95%CI:0.46-0.99)。
- 2至8个月各时间点MMF成功比例均高于MTX,9个月时趋同。
- 两组因毒性停药的发生率相似。
核心结论
- 作者认为,平均而言MMF在眼部炎症性疾病中达到激素节约成功可能比MTX更快。
研究设计与样本
- 对全身免疫抑制治疗眼病队列研究数据的回顾性分析,纳入352例在4家三级葡萄膜炎门诊接受MTX或MMF单药免疫抑制治疗的患者。
- 采用边际结构模型衍生统计加权构建协变量和删失模式在替代治疗间平衡的虚拟人群,以生存分析模拟比较MMF与MTX的临床试验。
主要发现
- MMF达到成功的时间较MTX更短(风险比=0.68,95%CI:0.46-0.99)。
- 调整协变量后,MMF在2至8个月各时间点达到成功的比例均高于MTX,9个月时趋同。
- 两组大多数患者激素节约成功的起效时间均超过3个月。
- MMF与MTX的治疗结局在所有炎症解剖部位间相似。
- 两组因毒性停药的发生率相似。
关键数值与推荐
- 主要结局为泼尼松≤10 mg/天条件下炎症完全控制并持续≥30天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare mycophenolate mofetil (MMF) to methotrexate (MTX) as corticosteroid-sparing therapy for ocular inflammatory diseases. DESIGN: Retrospective analysis of cohort study data. METHODS: Participants were identified from the Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study. Demographic and clinical characteristics were obtained via medical record review. The study included 352 patients who were taking single-agent immunosuppression with MTX or MMF at 4 tertiary uveitis clinics. Marginal structural models (MSM)-derived statistical weighting created a virtual population with covariates and censoring patterns balanced across alternative treatments. With this methodological approach, the results estimate what would have happened had none of the patients stopped their treatment. Survival analysis with stabilized MSM-derived weights simulated a clinical trial comparing MMF vs MTX for noninfectious inflammatory eye disorders. The primary outcome was complete control of inflammation on prednisone ≤10 mg/day, sustained for ≥30 days. RESULTS: The time to success was shorter (more favorable) for MMF than MTX (hazard ratio = 0.68, 95% confidence interval: 0.46-0.99). Adjusting for covariates, the proportion achieving success was higher at every point in time for MMF than MTX from 2 to 8 months, then converges at 9 months. The onset of corticosteroid-sparing success took more than 3 months for most patients in both groups. Outcomes of treatment (MMF vs MTX) were similar across all anatomic sites of inflammation. The incidence of stopping therapy for toxicity was similar in both groups. CONCLUSIONS: Our results suggest that, on average, MMF may be faster than MTX in achieving corticosteroid-sparing success in ocular inflammatory diseases.
引用
- Gangaputra SS, Newcomb CW, Joffe MM, et al. Comparison Between Methotrexate and Mycophenolate Mofetil Monotherapy for the Control of Noninfectious Ocular Inflammatory Diseases. Am J Ophthalmol. 2019. PMID: 31344346. doi:10.1016/j.ajo.2019.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。